Kathryn Humphrey

5.8k total citations · 1 hit paper
52 papers, 1.4k citations indexed

About

Kathryn Humphrey is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Kathryn Humphrey has authored 52 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Genetics, 36 papers in Pathology and Forensic Medicine and 20 papers in Oncology. Recurrent topics in Kathryn Humphrey's work include Chronic Lymphocytic Leukemia Research (36 papers), Lymphoma Diagnosis and Treatment (36 papers) and CAR-T cell therapy research (19 papers). Kathryn Humphrey is often cited by papers focused on Chronic Lymphocytic Leukemia Research (36 papers), Lymphoma Diagnosis and Treatment (36 papers) and CAR-T cell therapy research (19 papers). Kathryn Humphrey collaborates with scholars based in United Kingdom, United States and Australia. Kathryn Humphrey's co-authors include John F. Seymour, Thomas J. Kipps, Barbara Eichhorst, Michelle Boyer, Mehrdad Mobasher, Arnon P. Kater, Carolyn Owen, Peter Hillmen, Elizabeth A. Punnoose and Guillaume Cartron and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Kathryn Humphrey

49 papers receiving 1.4k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

2018 595 citations John F. Seymour, Thomas J. Kipps et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kathryn Humphrey United Kingdom	16	1.0k	920	433	369	320	52	1.4k
Deborah M. Stephens United States	22	1.0k 1.0×	1.1k 1.2×	630 1.5×	342 0.9×	354 1.1×	142	1.7k
Celeste Bello United States	13	640 0.6×	808 0.9×	544 1.3×	247 0.7×	250 0.8×	63	1.3k
John N. Allan United States	21	803 0.8×	708 0.8×	333 0.8×	319 0.9×	286 0.9×	97	1.1k
Mehrdad Mobasher United States	16	903 0.9×	672 0.7×	433 1.0×	386 1.0×	345 1.1×	39	1.4k
Manfred Hensel Germany	21	988 1.0×	903 1.0×	490 1.1×	517 1.4×	310 1.0×	68	1.6k
Amber Gordon United States	8	1.2k 1.2×	792 0.9×	340 0.8×	535 1.4×	357 1.1×	14	1.5k
Timothy J. Murphy United States	9	778 0.8×	799 0.9×	310 0.7×	399 1.1×	158 0.5×	19	1.2k
Andrew Haynes United Kingdom	15	655 0.6×	1.0k 1.1×	516 1.2×	370 1.0×	168 0.5×	36	1.3k
Lorenzo Falchi United States	20	520 0.5×	707 0.8×	569 1.3×	271 0.7×	257 0.8×	113	1.3k
William G. Wierda United States	18	1.8k 1.7×	1.4k 1.5×	358 0.8×	948 2.6×	351 1.1×	44	2.1k

Countries citing papers authored by Kathryn Humphrey

Since Specialization

Citations

This map shows the geographic impact of Kathryn Humphrey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kathryn Humphrey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kathryn Humphrey more than expected).

Fields of papers citing papers by Kathryn Humphrey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kathryn Humphrey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kathryn Humphrey. The network helps show where Kathryn Humphrey may publish in the future.

Co-authorship network of co-authors of Kathryn Humphrey

This figure shows the co-authorship network connecting the top 25 collaborators of Kathryn Humphrey. A scholar is included among the top collaborators of Kathryn Humphrey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kathryn Humphrey. Kathryn Humphrey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Phillips, Tycel, Carmelo Carlo‐Stella, Franck Morschhauser, et al.. (2024). Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study. Journal of Clinical Oncology. 43(3). 318–328. 18 indexed citations

Dickinson, Michael, Andreas Viardot, Reinhard Marks, et al.. (2023). Glofitamab + Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from a phase Ib study.. Journal of Clinical Oncology. 41(16_suppl). 7549–7549. 16 indexed citations

Dickinson, Michael, Carmelo Carlo‐Stella, Franck Morschhauser, et al.. (2022). Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and ≥ 2 prior therapies: Pivotal phase II expansion results.. Journal of Clinical Oncology. 40(16_suppl). 7500–7500. 15 indexed citations

Song, Yuqin, Huilai Zhang, Huiqiang Huang, et al.. (2022). Glofitamab Monotherapy Demonstrates High Complete Response Rates and Manageable Safety in Chinese Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and ≥2 Prior Therapies. Blood. 140(Supplement 1). 12050–12051. 2 indexed citations

Kim, Eugene, Yanwen Jiang, Alexandra Bazeos, et al.. (2022). Prognostic mutational subtyping in de novo diffuse large B-cell lymphoma. BMC Cancer. 22(1). 231–231. 5 indexed citations

Dickinson, Michael, Carmelo Carlo‐Stella, Franck Morschhauser, et al.. (2021). Glofitamab Monotherapy Provides Durable Responses after Fixed-Length Dosing in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (pts). Blood. 138(Supplement 1). 2478–2478. 9 indexed citations

Phillips, Tycel, Michael Dickinson, Franck Morschhauser, et al.. (2021). Glofitamab Step-up Dosing Induces High Response Rates in Patients (pts) with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Most of Whom Had Failed Prior Bruton's Tyrosine Kinase Inhibitor (BTKi) Therapy. Blood. 138(Supplement 1). 130–130. 20 indexed citations

Morschhauser, Franck, Carmelo Carlo‐Stella, Michael Dickinson, et al.. (2021). Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL). Blood. 138(Supplement 1). 128–128. 20 indexed citations

Carlo‐Stella, Carmelo, Cyrus Khan, Martin Hutchings, et al.. (2021). Oral Abstract: ABCL-360: Glofitamab Step-Up Dosing (SUD): Updated Efficacy Data Show High Complete Response Rates in Heavily Pretreated Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (Pts). Clinical Lymphoma Myeloma & Leukemia. 21. S203–S203.

10.

Mato, Anthony R., Jeff P. Sharman, Mei Wu, et al.. (2020). The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: <i>post-hoc</i> analyses from the phase III MURANO study. Haematologica. 107(1). 134–142. 11 indexed citations

11.

Mato, Anthony R., Jeff P. Sharman, Mei Wu, et al.. (2020). Impact of premature venetoclax (Ven) discontinuation/interruption on outcomes in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Phase III MURANO study results.. Journal of Clinical Oncology. 38(15_suppl). 8028–8028. 1 indexed citations

12.

Al‐Sawaf, Othman, Alexandra Bazeos, Sandra Robrecht, et al.. (2019). Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL). American Journal of Hematology. 94(9). 1002–1006. 5 indexed citations

13.

Deng, Rong, Leonid Gibiansky, Tong Lu, et al.. (2019). Exposure–response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study. Leukemia & lymphoma. 61(1). 56–65. 9 indexed citations

14.

Deng, Rong, Leonid Gibiansky, Tong Lu, et al.. (2019). Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study. Clinical Pharmacokinetics. 58(12). 1621–1634. 12 indexed citations

15.

Fan, Jinzhen, Christopher R. Bolen, Alexandra Bazeos, et al.. (2019). Recapitulation of Prognostic Mutational Subtyping Utilizing F1H in GOYA and CAVALLI and the Potential to Highlight Benefit of Targeted Therapy in De Novo DLBCL. Blood. 134(Supplement_1). 2788–2788. 1 indexed citations

16.

Greil, Richard, Graeme Fraser, Brian Leber, et al.. (2018). Efficacy and Safety of Ibrutinib (IBR) after Venetoclax (VEN) Treatment in IBR-Naïve Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Follow-up of Patients from the MURANO Study. Blood. 132(Supplement 1). 5548–5548. 7 indexed citations

17.

Kater, Arnon P., John F. Seymour, Peter Hillmen, et al.. (2018). Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. Journal of Clinical Oncology. 37(4). 269–277. 198 indexed citations

18.

Stilgenbauer, Stephan, Franck Morschhauser, Clemens‐Martin Wendtner, et al.. (2018). Safety and Efficacy of Venetoclax (VEN) in Combination with Bendamustine (B) Plus Rituximab (R) or Obinutuzumab (G) in Patients (pts) with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results from a Phase Ib Study (GO28440). Blood. 132(Supplement 1). 1859–1859.

19.

Flinn, Ian W., John G. Gribben, Martin J.S. Dyer, et al.. (2017). Safety, Efficacy and MRD Negativity of a Combination of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331). Blood. 130. 430–430. 14 indexed citations

20.

Seymour, John F., Thomas J. Kipps, Barbara Eichhorst, et al.. (2017). Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia - Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano Study. Blood. 130(Suppl_1). LBA–2. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact